Solution
Nearly 10 years' experience working on 400+ early phase studies across Canada & North America.
Canada is a preferred destination for early phase trials because of simple and fast regulatory stream and lucrative R&D cash refund scheme.
Our clinical team have almost 10 years' experience working on 400+ early phase studies, making us an exceptionally experienced local provider within the Canada & North America market and a partner of choice for many international biotech companies.
The regulatory environment in Canada and North America offers a significant strategic opportunity for international biotech companies who can take advantage of a uniquely fast and pragmatic regulatory pathway for early phase clinical trials.
The simplicity and efficiency of the Canada and North America Regulatory and Ethics (IRB) processes often means our clients can commence subject treatment within a single review cycle of 6–8 weeks from submission.
Receive a timely response to an enquiry about a service, process or technical questions.
